論文 - 詳細
| RRC ID | 68574 |
|---|---|
| 著者 | Akiyama M, Yamada O, Kanda N, Akita S, Kawano T, Ohno T, Mizoguchi H, Eto Y, Anderson KC, Yamada H. |
| タイトル | Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. |
| ジャーナル | Cancer Lett |
| Abstract |
Telomeres are specialized DNA/protein structures that act as protective caps to prevent end fusions. The maintenance of telomeres is essential for chromosomal stability. Telomerase is regulated by human telomerase reverse transcriptase (hTERT). c-Myc oncoprotein is also implicated in the positive regulation of hTERT expression. We show here that two clones of hTERT-transfected K562 erythroleukemia cells have elongated telomeres (22.5 and 24.0 kb), whereas telomere length of both c-Myc-transfected K562 cells and parental K562 cells is 6.5 kb. Telomerase activity and hTERT mRNA expression increased in hTERT-transfected K562 cells, while the expression levels of telomerase activity and hTERT in c-Myc-transfected K562 cells were similar to that in parental K562 cells, despite an overexpression of c-Myc. Importantly, we found that hTERT-transfected K562 cells are protected against apoptosis induced by serum deprivation and double-stranded DNA break inducing agents (ionizing irradiation, and etoposide (VP-16)), but not against DNA synthesis inhibitors (1-beta-D-arabinofuranosylcytosine and hydroxyurea). These findings suggest that overexpression of telomerase by transfecting hTERT confers telomere-elongation and resistance to double-stranded DNA break inducing agents. |
| 巻・号 | 178(2) |
| ページ | 187-97 |
| 公開日 | 2002-4-25 |
| DOI | 10.1016/s0304-3835(01)00838-2 |
| PII | S0304383501008382 |
| PMID | 11867204 |
| MeSH | Antineoplastic Agents / pharmacology Apoptosis / drug effects Apoptosis / genetics* Apoptosis / radiation effects Culture Media, Serum-Free Cytarabine / pharmacology DNA Damage / drug effects DNA Damage / genetics DNA Damage / radiation effects DNA Replication / drug effects Etoposide / pharmacology Humans Hydroxyurea / pharmacology K562 Cells / drug effects K562 Cells / enzymology* K562 Cells / pathology* K562 Cells / radiation effects Nucleic Acid Synthesis Inhibitors / pharmacology Telomerase / biosynthesis* Telomerase / genetics Telomere / pathology Transfection |
| IF | 7.36 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 4 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | K562(RCB0027) |